DBDominic Bertschi

Dominic Bertschi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dominic Bertschi has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Validation of Quality Indicators for the Pharmacological Management of Chronic Non-Cancer Pain in Older Adult Inpatients

    by Jasmin Abderhalden, Carla Meyer-Massetti, Danja Müller, Patricia Cadisch, Dominic Bertschi, Aljoscha Goetschi

    Chronic non-cancer pain (CNCP) affects up to 88% of older adults. Pharmacological therapies are frequently prescribed long-term despite being considered second-line treatments and carrying significant risks, particularly for older adults. The present study aimed to clinically validate a set of quality indicators (QIs) that are used to improve the detection of medication-related problems during medication reviews performed by pharmacists for older adult inpatients with CNCP. We evaluated a set of medication review QIs—with previously established face and content validity—for a population of older adult inpatients diagnosed with CNCP. Subjects were in geriatrics wards in a tertiary hospital in Switzerland. Over two phases, pre- and post-QI implementation (Phase 1: July 2023 to April 2024, Phase 2: January to May 2025), pharmacists evaluated QIs for their applicability to the population, potential to improve medication reviews, acceptability by pharmacists, implementation issues and impact. These domains were used to evaluate the measurement properties of QIs in clinical practice, acting as proxies for clinical validity. Evaluations were interpreted using descriptive statistics. We included 89 patients in phase 1 and 48 in phase 2. Of the 38 QIs evaluated, 27 (71%) were applicable to ≥ 5% of patients, 21 (55%) showed the potential to improve medication reviews, 12 (32%) revealed relevant treatment discrepancies that pharmacists accepted, 6 (16%) were rated as problematic to implement, 10 (37%) were impactful according to our predefined criterion and 6 (16%) met all criteria. The clinical evaluation of our set of previously developed QIs could help pharmacists to efficiently detect medication-related problems among vulnerable older adult populations with CNCP. The fact that only a few of the QIs were clinically valid means that future research is required, including the measurement of the influence of these QIs on patient-reported outcomes.

  • Open Access

    Implementing a clinical pharmacy intervention for older adult inpatients with chronic non-cancer pain: a feasibility study

    by Jasmin Abderhalden, Céline Lang, Carla Meyer-Massetti, Danja Müller, Patricia Cadisch, Dominic Bertschi, Aljoscha Noël Goetschi

    Introduction: Chronic non-cancer pain (CNCP) affects 22–88% of older adults and is associated with a lower quality of life and polypharmacy. It thus puts these already very vulnerable patients at a greater risk of medication-related harm. Aim: This feasibility study aimed to implement a multimodal clinical pharmacy intervention to improve CNCP-related care for older adult inpatients on hospital geriatrics wards. Method: We conducted a single-arm feasibility study from January to May 2025, including patients aged 65 or older, hospitalised on the geriatrics ward of a tertiary hospital in Switzerland and previously diagnosed with CNCP. Feasibility was defined as the ability to perform the intervention as planned and approximated by recruitment and dropout rates. The intervention included semi-structured interviews about patients’ pain histories, collected patient-reported outcome measures (PROMs) and recorded therapy goals. Pharmacists then conducted medication reviews using a previously developed and validated trigger tool. The trigger tool was used as a standardised approach for identifying medication-related issues, comprising a set of previously validated quality indicators. Findings were discussed during interprofessional ward rounds. Final treatment decisions were made jointly with patients. We followed up with patients by telephone one month after hospital discharge. Results: Of 253 screened patients, we included 48 patients: 28 (58%) were interviewed, and 18 (38%) had a follow-up telephone call. Pharmacists suggested 56 therapy changes, with 29 identified by the trigger tool and 27 identified by regular medication review. Therapy change acceptance rates by the care team were 78% and 41%, respectively. Pain frequency and the highest and lowest pain levels over the last seven days all decreased after hospital discharge, although these changes cannot be causally attributed to the intervention. Other pain-related PROMs showed no change or just a slight improvement or deterioration. Conclusion: The present feasibility study showed that implementing a clinical pharmacy intervention for older adult inpatients was indeed feasible. However, the recruitment rates were relatively low, and dropout rates were relatively high. Using a standardised approach involving a trigger tool showed promising results for detecting medication-related problems. These are important first indicators that including pharmacists more closely in standard care could be beneficial to CNCP patients.


  • Open Access

    Impact of sarcopenia on daily functioning: a cross-sectional study among older inpatients

    by Dominic Bertschi, Caroline M. Kiss, Nadine Beerli, Oliver Mauthner, Reto W. Kressig

    Background and aim: Geriatric patients with sarcopenia are at increased risk for functional decline with loss of independence in daily living. This cross-sectional study aims to investigate the impact of sarcopenia on different domains of functional status in hospitalized geriatric patients. Methods: Sarcopenia was assessed at hospital admission using the recommendations of the European Working Group on Sarcopenia in Older People 2 (EWGSOP2). Body impedance analysis (BIA) was performed to determine muscle mass, and a pneumatic hand dynamometer was used to assess muscle strength. The functional independence measure (FIM) score, an 18-item tool exploring an individual's physical, cognitive and social functions, was used to measure functional status. Results: In 305 included inpatients with a median age of 84.0 years (65.6% female), prevalence of sarcopenia was 22.6%. Overall, sarcopenic patients had significant lower FIM scores compared to non-sarcopenic patients (p = 0.006). An association with sarcopenia was found for the FIM items bed/chair/wheelchair transfer (p = 0.047), transfer to toilet (p = 0.048), locomotion (p = 0.001), climbing stairs (p = 0.012), comprehension (p = 0.029), and social interaction (p = 0.028). Conclusion: In hospitalized geriatric patients, sarcopenia was found to be associated with both cognitive and mobility domains, but not with self-care domains of the FIM score. Therefore, when addressing sarcopenia in inpatients, tailored and multi-dimensional training interventions mainly should focus on motor-cognitive abilities.


  • Open Access

    The experiences of early career geriatricians throughout Europe during the COVID-19 pandemic

    by Vojtech Mezera, Anne W. Ekdahl, Dominic Bertschi, Maria Bonnici, Rui Buzaco, Santiago Cotobal Rodeles, Kseniia Eruslanova, Lubov Matchekhina, Laura Monica Perez Bazan, Itxaso Marin Epelde, et al.

    Key summary points AbstractSection Aim To assess the experiences of early career geriatricians during the COVID-19 pandemic. AbstractSection Findings The respondents reported moderate levels of anxiety, work overload, and strong disruption in their work routine and private lives. AbstractSection Message Many early career geriatricians throughout Europe were involved as frontline workers in the care of older adults with COVID-19, and experienced a major impact on their professional and private lives.


  • Open Access

    Performance of the EWGSOP2 Cut-Points of Low Grip Strength for Identifying Sarcopenia and Frailty Phenotype: A Cross-Sectional Study in Older Inpatients

    by Anna K. Stuck, Nina C. Mäder, Dominic Bertschi, Andreas Limacher, Reto W. Kressig

    Background: The European Working Group on Sarcopenia has recently proposed revised cut-off values for the definition of low grip strength (EWGSOP2). We therefore compared performance of the EWGSOP2 cut-off definition of low grip strength with other internationally used cut-off points in a sample of older patients. Methods: We analyzed geriatric assessment data in a cross-sectional sample of 98 older patients admitted to a post-acute care hospital. First, we compared prevalence of sarcopenia and frailty phenotype in our sample using low grip strength cut-points from the EWGSOP2 and seven other internationally used consensus statements. Second, we calculated correlations between low grip strength and two independent surrogate outcomes (i.e., gait speed, and the clinical frailty scale) for the EWGSOP2 and the other seven cut-point definitions. Results: Prevalence of sarcopenia based on the EWGSOP2 grip strength cut-off values was significantly lower (10.2%) than five of the seven other cut-point definitions (e.g., 19.4% based on Sarcopenia Definitions and Outcomes Consortium (SDOC) criteria). Similarly, frailty phenotype prevalence was significantly lower based on EWGSOP2 cut-points (57.1%) as compared to SDOC (70.4%). The correlation coefficient of gait speed with low grip strength based on EWGSOP2 cut-points was lower (0.145) as compared to other criteria (e.g., SDOC 0.240). Conclusions: Sarcopenia and frailty phenotype were identified considerably less using the EWGSOP2 cut-points for low grip strength, potentially underestimating prevalence of sarcopenia and frailty phenotype in post-acute hospital patients.


  • Open Access

    Sarcopenia in hospitalized geriatric patients: insights into prevalence and associated parameters using new EWGSOP2 guidelines

    by Dominic Bertschi, Caroline M. Kiss, Nadine Beerli, Reto W. Kressig

    Background: Data on prevalence of sarcopenia and its associated parameters in hospitalized geriatric patients are heterogeneous due to various definitions of the disease. The aim of this study was to determine the prevalence of sarcopenia using latest recommendations of the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and to investigate associated parameters in patients admitted to acute geriatrics and geriatric rehabilitation. Methods: In this cross-sectional single-centre study including 305 hospitalized geriatric patients, handgrip strength (pneumatic hand dynamometer) and muscle quantity (body impedance analysis) were assessed. Probable sarcopenia was defined by low handgrip strength, and the diagnosis was confirmed when both handgrip strength and muscle quantity were below cut-off points. Furthermore, parameters of the geriatric baseline examination were analyzed for association with probable and confirmed sarcopenia using logistic regression models. Results: Median age of the study population was 84.0 years, and 65.6% were female. The prevalence of probable sarcopenia was 24.6% (CI 19.8–29.4%), and the prevalence of confirmed sarcopenia was 22.6% (CI 17.9–27.3%). Low calf circumference, low body mass index, cognitive impairment and an increased risk of malnutrition were found to be associated with confirmed sarcopenia. In contrast, only cognitive impairment was positively associated with probable sarcopenia. Conclusions: Sarcopenia is highly prevalent in geriatric inpatients, and multiple parameters were found to be associated with the disease. To reduce negative clinical outcomes, our findings support the need for routinely performed admission examinations for prompt diagnosis of sarcopenia, and a timely start of treatment in hospitalized geriatric patients.


  • Open Access

    Sarcopenia in Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI): A Systematic Review of the Literature

    by Dominic Bertschi, C. M. Kiss, A. W. Schoenenberger, A. E. Stuck, R. W. Kressig


  • Open Access

    Hormonal Contraceptive Use and the Prevalence of Endometriotic Lesions at Different Regions within the Peritoneal Cavity

    by Brett D. McKinnon, Dominic Bertschi, Juilette Wanner, Nick A. Bersinger, Michael D. Mueller

    Endometriosis is an estrogen-dependent disease that can lead to chronic pain and subfertility. Endometriotic lesions found in different locations are heterogeneous and may represent a collection of related but distinct conditions. Whether there is a relationship between hormonal contraceptive (HC) use and endometriosis is still controversial. The purpose of this study was to determine whether HC use affected the prevalence of endometriotic lesions differently based on lesion location. Data was retrospectively collected from 161 patients presenting to the Berne University Women’s Hospital between 2008 and 2012 for laparoscopic investigation. Women with histologically proven endometriosis were included in the study and patients were grouped according to lesion location and HC use. The results of the study indicate that HC users are significantly less likely to have endometriotic lesions on the ovaries, although in contrast, no difference was observed in the incidence of lesions in the rectovaginal septum (RVS) or peritoneal region. In addition, women using HC who were diagnosed with endometriotic lesions on the peritoneum were significantly younger than women with lesions in other locations. In conclusion, women with endometriosis who are currently using HC are less likely to have ovarian endometriotic lesions than in alternate locations.


  • Open Access

    Enhanced Inflammatory Activity of Endometriotic Lesions from the Rectovaginal Septum

    by Dominic Bertschi, Brett D. McKinnon, Jakob Evers, Nick A. Bersinger, Michael D. Mueller

    Endometriosis is characterised by the growth of ectopic lesions at multiple locations outside the uterine cavity and may be considered a collection of distinct but related conditions. The exact aetiology of endometriosis is still not clear although a role for inflammation is increasingly accepted. We therefore investigated the inflammatory activity of eutopic tissue and that of the matching ectopic lesions from different locations by measuring the genetic expression of inflammatory chemokines and cytokines. The gene expression in matching eutopic and ectopic tissue was compared, as was the gene expression in lesions from different locations. A significantly higher mRNA expression of the chemokines ENA-78 and RANTES and the cytokines IL-6 and TNFαwas observed in endometriotic lesions of the rectovaginal septum (RVS) compared to that of matching eutopic tissue. Comparisons across lesion locations showed a significantly higher expression of IL-6 and TNFαin the RVS compared to lesions from either the ovaries or the peritoneum. These results show that the production of some inflammatory chemokines and cytokines is significantly increased in the ectopic endometrial tissue compared to matching eutopic tissue. Furthermore, IL-6 and TNFαare produced in significantly higher quantities in RVS lesions compared to other lesions.